Fairvalue-Calculator Fairvalue-Calculator
EN DE

Vir Biotechnology, Inc (VIR) Fair Value & Analysis

Healthcare · US · Market cap $1.7B

Price$9.95
Fair Value$1.64
Upside-83.5%
Quality95/100
Evidence: Low Range $1.08 – $2.05

Fair value as of: Jun 25, 2026

Analysis

Vir Biotechnology, Inc (VIR) currently trades at $9.95, while our model-based Fair Value estimate is $1.64 — implying the stock looks roughly 83.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockef…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Vir Biotechnology, Inc (VIR) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.64 versus a price of $9.95 — about −84% (overvalued). Model-based estimate, not financial advice.
What is the fair value of VIR?
Our 21-model fair value for Vir Biotechnology, Inc is $1.64 (as of Jun 25, 2026), built from audited fundamentals. The current price is $9.95.
What is the quality score of VIR?
Vir Biotechnology, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.